MCP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits
PARSIPPANY, NJ MAY 10, 2010 — MCP Pharmaceuticals’ sterile manufacturing site based in Rochester, Michigan completed a successful GMP (Good Manufacturing Practices)/Pre Approval Audit by the U.S. Food and Drug Administration (FDA) drug division (CDER). This audit followed two successful GMP audits in 2009 including an audit by the FDA biologics division (CBER) and an audit by the European Medicines Agency (EMEA), which resulted in a continuance of the certificate of GMP compliance for the manufacturing site. Stuart Hinchen, co-founder and President of MCP stated, “We are extremely pleased with the results of the recent audits of our Rochester, Michigan sterile injectable manufacturing facility. We understand the importance of compliant quality systems and we work diligently to maintain these systems to the highest global standards.”
About MCP Pharmaceuticals, LLC
MCP Pharmaceuticals, headquartered in New Jersey, is a specialty pharmaceutical company that manufactures and sells sterile injectable products for the hospital market segment, and provides contract manufacturing of sterile injectable products for innovator pharmaceutical and biotech organizations.
MCP markets 14 branded pharmaceutical products through its national sales and marketing infrastructure and contract manufactures both pharmaceutical and biotechnology products for small and large proprietary pharmaceutical and biotechnology companies. MCP employs more than 330 staff in the USA in its manufacturing, sales & marketing and corporate areas. MCP is a private company wholly owned by MCP Holdings, LLC. For more information, please visit jhppharma.com
Additional Press Releases |
04/17/13 |
MCP Pharmaceuticals To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials |
|
Webpage | PDF Format |
|
|
12/31/12 |
MCP Pharmaceuticals Acquired By Warburg Pincus |
|
Webpage | PDF Format |
|
|
09/19/12 |
MCP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials |
|
Webpage | PDF Format |
|
|
06/07/12 |
MCP Pharmaceuticals Launches Generic Division |
|
Webpage | PDF Format |
|
|
06/05/12 |
MCP Pharmaceuticals to Produce Clinical and Commercial Supply of an Innovative Injectable |
|
Webpage | PDF Format |
|
|
02/29/12 |
MCP Pharmaceuticals Adds Second Product To Multi-Year Contract Manufacturing Agreement |
|
Webpage | PDF Format |
|
|
10/18/11 |
MCP Pharmaceuticals Enters Agreement to Produce Diagnostic Aid |
|
Webpage | PDF Format |
|
|
07/25/11 |
MCP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug |
|
Webpage | PDF Format |
|
|
07/06/11 |
MCP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug |
|
Webpage | PDF Format |
|
|
07/05/11 |
MCP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin® |
|
Webpage | PDF Format |
|
|
06/24/11 |
MCP Pharmaceuticals Announces Chief Executive Officer Succession |
|
Webpage | PDF Format |
|
|
03/28/11 |
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement |
|
Webpage | PDF Format |
|
|
02/24/11 |
MCP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement |
|
Webpage | PDF Format |
|
|
01/27/11 |
MCP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement |
|
Webpage | PDF Format |
|
|
06/29/10 |
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement |
|
Webpage | PDF Format |
|
|
05/10/10 |
MCP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits |
|
Webpage | PDF Format |
|
|
09/28/09 |
MCP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds |
|
Webpage | PDF Format |
|
|
08/20/08 |
MCP Pharmaceuticals & SpePharm complete purchaseof Dantrium® (dantrolene sodium) |
|
Webpage | PDF Format |
|
|
07/16/07 |
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To MCP Pharmaceuticals |
|
Webpage | PDF Format |
|
|
Return To Press Releases »